CXCR6 and metabolic dysfunction-associated steatotic liver disease: Ameliorates NAFLD by the restoration of intestinal barrier [184, 185]. Suppresses NASH-associated tumorigenesis through expansion of CXCR6+ NKT cells [186]. Ameliorates oxidative stress-induced cell apoptosis, increased the levels of l-aspartate in the liver [201].